Curcumin-low-molecular-weight PEGs (mPEG454) showed a therapeutic effect on dyslipidemia and nonalcoholic fatty liver disease via cAMP response element binding (CREB)/PPARγ/CD36 pathway, by which the activation of CREB triggered inhibition of PPARγ and CD36 expression in mediation of lipid homeostasis [25]. The gene discussed is CREB1; the disease is metabolic syndrome.